Meeting
2017 Gastrointestinal Cancers Symposium
Long-standing Crohn’s disease and its implication on anal squamous cell cancer management.
Authors
Sara Moncrief
Mayo Clinic, Rochester, MN
Sara Moncrief , Kellie L. Mathis , Amy Lightner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 576)
DOI
10.1200/JCO.2017.35.4_suppl.576
Abstract #
576
Poster Bd #
C16
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
First Author: Yoanna S Pumpalova
Poster
2014 ASCO Annual Meeting
A comparison between 5-fluorouracil/mitomycin (FM) and capecitabine/mitomycin (CM) in combination with radiation (RT) for squamous cell carcinoma (SCC) of the anal canal.
First Author: Dante D.C. Wan
Poster
2012 Gastrointestinal Cancers Symposium
Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.
First Author: Melissa Pulfer Mitchell
Poster
2018 ASCO Annual Meeting
Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.
First Author: Jaime Feliu